< Back to previous page
Project
IOF Accelerator: “FLT imaging using Nanobodies: effective tool for life sciences and medical applications (NLITE) (IOFACC10B)
The IOF GEAR NLITE is an interdisciplinary consortium that aims to advance novel technologies for image-guided surgery into clinical applications. Part of the research is dedicated to the development of single-domain antibody (sdAb)-based contrast agents that specifically bind to cancer-associated protein markers for pre- and/or intraoperative visualization of cancerous tissue. We now have identified a clear unmet clinical need for colorectal cancer patients, which can be addressed with a radiolabeled and/or fluorescently labeled sdAb targeting an unchallenged biomarker for colorectal cancer. This sdAb has previously been validated preclinically in relevant animal models. Our vision is to achieve better clinical decision-making through advanced imaging strategies leading to a more clinical- and cost-effective deployment of treatment options. This is expected to lead to a better selection and follow-up of colorectal cancer patients eligible for omitting surgery, and when surgery is inevitable, will guarantee a more complete resection of the tumor.
Before we can proceed towards clinical valorization, we need cGMP-grade sdAb that can be administered to patients. Unfortunately, cGMP-production generally creates a bottleneck for the clinical translation of molecular tracers as it is difficult to find financial recourses for this essential development step. We request an IOF Accelerator to finance the optimalization of an in-house cGMP production process and set-up of a quality assurance system for subsequent release of cGMP produced compounds. By lowering the development costs and focusing more on the patient studies themselves, we can position ourselves in a more competitive position for future funding and we can drastically accelerate the initiation of clinical trials..
Before we can proceed towards clinical valorization, we need cGMP-grade sdAb that can be administered to patients. Unfortunately, cGMP-production generally creates a bottleneck for the clinical translation of molecular tracers as it is difficult to find financial recourses for this essential development step. We request an IOF Accelerator to finance the optimalization of an in-house cGMP production process and set-up of a quality assurance system for subsequent release of cGMP produced compounds. By lowering the development costs and focusing more on the patient studies themselves, we can position ourselves in a more competitive position for future funding and we can drastically accelerate the initiation of clinical trials..
Date:1 Oct 2022 → 2 Mar 2024
Keywords:colorectal cancer, personalized therapy, molecular imaging
Disciplines:Cancer therapy
Project type:Collaboration project